Allurion Technologies has achieved significant regulatory milestones in its pursuit of FDA approval for the Allurion Smart Capsule, passing critical inspections with zero findings while securing $5 million in financing to support potential U.S. commercialization of its swallowable gastric balloon technology.
FDA Review Process Advances with Clean Inspections
The company submitted the fourth and final module of its Pre-Market Approval (PMA) application in June 2025, followed by successful completion of the FDA's Acceptance and Filing Reviews in July 2025, which advanced the submission into Substantive Review phase.
In August 2025, Allurion successfully passed the FDA's pre-approval inspection with zero findings, no observations raised, and no Form 483 issued. The pre-approval inspection assessed the company's systems, methods, and procedures to ensure effective establishment of the quality management system, covering compliance with regulatory requirements, process quality, and documentation standards.
The company underwent an additional Bioresearch Monitoring (BIMO) inspection by the FDA in October 2025, designed to assess clinical trial systems, methods, and procedures to ensure data integrity. Again, no observations were raised and no Form 483 was issued.
"Passing these FDA inspections with no findings and completing the Day-100 Meeting are major milestones for Allurion, and we believe we are now entering the final stages of the review process," said Dr. Shantanu Gaur, Founder and Chief Executive Officer of the company. "This achievement is a testament to our commitment to upholding the highest quality standards across our entire company and is another step towards Allurion serving the U.S. market, pending FDA approval."
Day-100 Meeting Completed Without Additional Data Requests
Also in October 2025, the company held its Day-100 Meeting with the FDA, where the agency provided feedback after reviewing the PMA submission. Notably, the FDA did not request any additional human clinical data, suggesting the existing clinical evidence package may be sufficient for the review process.
Financial Restructuring and New Investment
Allurion announced a transaction to exchange all outstanding debt under its Revenue Interest Financing Agreements for shares of newly created Series B Convertible Preferred Stock. If completed, the exchange would result in the company becoming debt-free. The Series B Preferred Stock will be convertible into common shares at $3.37 per share and will accrue an annual dividend of 8.25 percent, payable in cash or in kind.
The completion of the exchange is subject to stockholder approval and compliance with listing requirements of the national securities exchange where the common stock is listed.
"As we pursue FDA approval and a potential U.S. launch of the Allurion Smart Capsule, we wanted to have a clear path to being debt-free, and this transaction provides that path," said Dr. Gaur.
$5 Million Private Placement Strengthens Position
Alongside the debt exchange, the company completed a private placement financing totaling approximately $5 million through the sale of 2,994,012 shares of common stock and accompanying warrants at a purchase price of $1.67 per share. The financing included participation from new and existing stockholders, as well as a strategic investor with expertise in obesity.
Roth Capital Partners acted as the sole placement agent for the private placement. The proceeds will be used for working capital and general corporate purposes as the company prepares for potential U.S. commercialization of the Allurion Smart Capsule.
Smart Capsule Technology and Market Position
The Allurion Smart Capsule represents the world's first and only swallowable, procedureless gastric balloon for weight loss. The technology is part of the broader Allurion Program, which combines the Smart Capsule with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale.
The Smart Capsule remains an investigational device in the United States until formal FDA approval is obtained. The company continues to market its broader program internationally while pursuing U.S. market entry.
